4th International AIDS Society Conference on HIV Pathogenesis and Treatment Sydney, Australia - July 22 - 25, 2007

24-WEEK EFFICACY AND SAFETY OF NEVIRAPINE: 400 MG VERSUS 600 MG BASED HAART IN HIV-INFECTED PATIENTS WITH ACTIVE TUBERCULOSIS RECEIVING RIFAMPICIN

IAS Conf HIV Pathog Treat 2007 Jul 22-25;4th: Abstract No. MOAB102

Manosuthi W.¹, Avihingsanon A.², Kantipong P.³, Chuchotaworn C.⁴, Moolphate S.⁵, Sakornjun W.², Yamada N.⁵, Yanai H.⁵, Phanuphak P.², Burger D.⁶, Ruxrungtham K.^7
1Bamrasnaradura Institute, Nonthaburi, Thailand, ²HIV-NAT, Thai Red Cross AIDS Research Centre, Bangkok, Thailand, ³Chiangrai Hosp, Chiangrai, Thailand, ⁴Chest Disease Institute, Nonthaburi, Thailand, ⁵TB/HIV research project, RIT-JATA, Chiangrai, Thailand, ⁶Radbound University Medical Centre, Amsterdam, Netherlands, ⁷Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand

OBJECTIVES: Nevirapine (NVP) fixed dose combinations are widely used in resource limited settings where the tuberculosis (TB) burden is high. This study was to determine the appropriate dose of NVP in HIV/TB co-infected patients receiving RIF.

METHODS: 32 HIV-TB co-infected adults (16 per arm) with CD4< 200 cells/µL and active TB, receiving RIF 2-6 weeks were randomized to receive NVP 400 (NVP400) or 600 mg (NVP600) per day plus 2NRTIs. A NVP lead-in was performed at 200 mg QD (NVP400) and 200 mg BID (NVP600) for 2 weeks. Plasma NVP levels were obtained at week 2, 4, and 12 by HPLC.

RESULTS: Baseline characteristics were comparable among two groups. Median NVP C_min levels at week 2 were significantly lower in NVP400 (1.9 vs 4.83, p=0.001). There were more cases of NVP C_min levels < 3.1 mg/L at week 2 in NVP400 (79% vs 19%, p=0.002). However, NVP C_min was comparable at week 4 (4.05 vs 5.84, p=0.06) and week 12 (4.27 vs 5.53, p=0.24). NVP600 had a higher trend to NVP hypersensitivity (31vs 6%, p=0.07) and study discontinuation (44 vs 25%, p=0.23). Two HIV/HCV (NVP600) and 1 HIV/HBV patients (NVP400) had grade-2 ALT elevation. The 24-week efficacy showed no difference in the proportion with HIV RNA < 50c/mL (62 vs 50 % by ITT; p=0.49, and 83 vs 89% by OT) and the median (IQR) CD4 rise [106 (63.5-172.5) vs 44 (34.5-101) p=0.07].

CONCLUSIONS: A high percentage of suboptimal levels were found in the 200 mg qd lead-in period whereas the NVP 200mg BID lead in was associated with drug hypersensitivity. However, NVP dosed at 200mg BID as part of combination ART with 200 mg qd lead-in provided potent virological suppression and good CD4 response over 24 weeks observation. NVP 200 mg BID should be sufficient for most Thai HIV-infected patients receiving RIF.

Download PDF of this abstract.

Download Power Point Presentation.

2007-07-22
MOAB102
TB / HIV: Still a Deadly Partnership

Copyright © 2007 - International AIDS Society (IAS). All information and content relating to the abstracts from the 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment, such as text, graphics, logos, button icons, images, audio clips, and software is protected by copyright. Permission is hereby granted for the non-commercial use or reproduction of the information on this web site, provided that the use of such information is accompanied by an acknowledgement that IAS is the source of the information and the name of the author of the article.

AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2007. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2007. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. Permission is hereby granted for the non-commercial use or reproduction of the information herein, provided that the use of such information is accompanied by an acknowledgement that IAS is the source of the information and the name of the author of the article.